The duodenal mucosa in patients with renal failure: response to 1,25(OH)2D3.
The structure of the duodenal mucosa was evaluated in duodenal biopsy samples obtained from patients with moderate renal failure (MRF) and in dialysis patients (HD) in an effort to examine the possibility that changes in duodenal mucosa may contribute to the impaired calcium absorption in renal failure (RF). The effect of therapy with 1,25(OH)2D3 on the duodenal mucosa in the HD patients was also studied. The results show that both MRF and HD patients have reduction in calcium reabsorption and in the length of their intestinal villi and crypts of Lieberkuhn. In the HD patients, these structural changes were more severe. Treatment with 1,25(OH)2D3 produced significant improvement in calcium reabsorption (P less than 0.01) as well as in length of villus and crypt (P less than 0.02) and increased mitotic activity in the crypts (P 0.02). Electron microscopy revealed the microvilli to be shorter, irregularly distributed, moth-eaten, and grainy, with these abnormalities disappearing after treatment. The data show that duodenal mucosa in RF exhibits structural abnormalities, which were normalized after 1,25(OH)2D3 therapy, and suggest that these derangements may play a role in the defective calcium reabsorption in RF.
D000328:Adult; D002117:Calcitriol; D002118:Calcium / Q000378:metabolism; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use*; D004386:Duodenum / Q000648:ultrastructure*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D007413:Intestinal Mucosa / Q000648:ultrastructure*; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D002117:Calcitriol; D002118:Calcium